17/07/2026 China NMPA grants approval to iza‑bren, delivering survival benefit in recurrent/metastatic ESCC after PD‑1/PD‑L1 therapy China NMPA grants approval to iza‑bren, delivering survival benefit in recurrent/metastatic ESCC after PD‑1/PD‑L1 therapy (Ref) China’s NMPA approved Biokin Pharma's iza-bren (izalontamab brengitecan; EGFR x HER3 bispecific ADC) for recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after progression on platinum-based chemotherapy